The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
1995
year mood +0.44 · +0.30 to +0.53 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.75 -0.38 0 +0.38 +0.75 Jan +0.53 Feb +0.30 Mar Apr May Jun Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.53+0.30+0.40+0.40+0.40+0.40+0.40+0.40+0.50+0.50+0.50+0.50

Healthcare sentiment is moderately bullish this month, driven primarily by Glaxo’s $14.24 billion hostile bid for Wellcome, a significant move signaling intensified consolidation within the pharmaceutical segment. This high-profile acquisition underscores confidence in long-term sector growth and pipeline synergies, supporting broader optimism despite a neutral macro backdrop.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 1995
Jan
Glaxo makes $14.24B hostile bid for Wellcome in major pharma consolidation spokesman.com →

Glaxo PLC has launched a $14.24 billion unsolicited offer to acquire rival UK drugmaker Wellcome PLC, aiming to create the world’s largest pharmaceutical company by revenue. The deal, driven by expiring drug patents and industry consolidation, would combine key products like Zantac and AZT, enabling significant cost savings and market expansion. Wellcome’s board has urged shareholders to wait, while markets reacted with a sharp rise in Wellcome’s stock and a drop in Glaxo’s.